AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15200749 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion yearly
Number of subjects: 1714
Study 11489699 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic prostatitis
Number of subjects: 46
Study 11489699 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic bacterial prostatitis
Number of subjects: 46
Study 11489699 — intervention group
Group type: COMPARATOR
Intervention: Comparison with controls
Number of subjects: 46
Study 9728832 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp infiltration with bupivacaine (0.25%) and epinephrine (1:200,000)
Number of subjects: 36
Study 9728832 — intervention group
Group type: COMPARATOR
Intervention: Saline/epinephrine (1:200,000)
Number of subjects: 36
Study 7826961 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (verum)
Number of subjects: 64
Study 7826961 — intervention group
Group type: COMPARATOR
Intervention: 5% human albumin (placebo)
Number of subjects: 64
Study 3396401 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral placebo (single dose)
Number of subjects: 19
Study 3396401 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral placebo (1-2 weeks of therapy)
Number of subjects: 19
Study 3396401 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral placebo (Group 1)
Number of subjects: 19
Study 3396401 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral placebo (Group 2)
Number of subjects: 19
Study 29457876 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg single dose
Number of subjects: 20
Study 27297718 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (1000 mg/d)
Number of subjects: 117
Study 25045865 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about food consumption of overweight individuals
Number of subjects: 80
Study 25045865 — intervention group
Group type: COMPARATOR
Intervention: Information about food consumption of normal/healthy weight individuals
Number of subjects: 80
Study 22525385 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast alone
Number of subjects: 137
Study 22525385 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast plus add-on loratadine
Number of subjects: 137
Study 22525385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 21122699 — intervention group
Group type: EXPERIMENTAL
Intervention: ERN/LRPT 1 g
Number of subjects: 1613
Study 21122699 — intervention group
Group type: EXPERIMENTAL
Intervention: ERN 1 g
Number of subjects: 1613
Study 21122699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1613
Study 18295172 — intervention group
Group type: EXPERIMENTAL
Intervention: Human papillomavirus/Papanicolaou test smear group
Number of subjects: 674
Study 18295172 — intervention group
Group type: COMPARATOR
Intervention: Papanicolaou test smear only group
Number of subjects: 674
Study 15791966 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomeroy ligation
Number of subjects: 109
Study 15791966 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar coagulation
Number of subjects: 109
Study 11814493 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal metronidazole, 37.5 mg twice daily for 5 days
Number of subjects: 106
Study 11814493 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel twice daily for 5 days
Number of subjects: 106
Study 11814493 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal metronidazole
Number of subjects: 106
Study 11814493 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 106
Study 10748847 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal splints
Number of subjects: 110
Study 10748847 — intervention group
Group type: COMPARATOR
Intervention: Non-splinted group
Number of subjects: 110
Study 8748566 — intervention group
Group type: COMPARATOR
Intervention: Nefazodone
Number of subjects: 2000
Study 1663860 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 303
Study 1663860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 6994789 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoeopathic remedies
Number of subjects: 23
Study 6994789 — intervention group
Group type: COMPARATOR
Intervention: Inert preparation (placebo)
Number of subjects: 23
Study 31552981 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg free EA
Number of subjects: 0
Study 31552981 — intervention group
Group type: COMPARATOR
Intervention: 237 mL PomJ (∼120 mg of EA)
Number of subjects: 0
Study 27913970 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (LLLT)
Number of subjects: 34
Study 27913970 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 34
Study 26475500 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia-based intervention consisting of 12 brief contact interventions (BCIs) delivered over six months.
Number of subjects: 630
Study 26475500 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 630
Study 22712831 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza virus positive individuals
Number of subjects: 586
Study 22712831 — intervention group
Group type: EXPERIMENTAL
Intervention: Other respiratory viruses
Number of subjects: 586
Study 22712831 — intervention group
Group type: COMPARATOR
Intervention: Virus negative population (reference)
Number of subjects: 586
Study 21323872 — intervention group
Group type: EXPERIMENTAL
Intervention: Senicapoc
Number of subjects: 289
Study 21323872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 19328861 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone with food
Number of subjects: 16
Study 19328861 — intervention group
Group type: COMPARATOR
Intervention: Pirfenidone without food
Number of subjects: 16
Study 17238034 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography
Number of subjects: 0
Study 15895314 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise/calcium
Number of subjects: 113
Study 15895314 — intervention group
Group type: COMPARATOR
Intervention: exercise/placebo
Number of subjects: 113
Study 15895314 — intervention group
Group type: COMPARATOR
Intervention: sedentary/calcium
Number of subjects: 113
Study 15895314 — intervention group
Group type: COMPARATOR
Intervention: sedentary/placebo
Number of subjects: 113
Study 17943665 — intervention group
Group type: EXPERIMENTAL
Intervention: GAME(Wheels) system
Number of subjects: 10
Study 17943665 — intervention group
Group type: COMPARATOR
Intervention: Without GAME(Wheels) system (control)
Number of subjects: 10
Study 9815298 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN beta ser, 9 MU subcutaneously, three times a week (Arm A)
Number of subjects: 81
Study 9815298 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN beta ser, 9 MU subcutaneously every day (Arm B)
Number of subjects: 81
Study 9815298 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN beta ser, 9 MU subcutaneously every day + sargramostim, 250 micrograms subcutaneously on non-5-FU days (Arm C)
Number of subjects: 81
Study 9815298 — intervention group
Group type: COMPARATOR
Intervention: All arms received 5-FU, 750 mg/m2 intravenously as an infusion daily for 5 days, followed by 5-FU, 750 mg/m2, as an intravenous bolus every week beginning day 15.
Number of subjects: 81
Study 9815298 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN beta ser on intermittent schedule (Arm A)
Number of subjects: 81
Study 7708002 — intervention group
Group type: EXPERIMENTAL
Intervention: octreotide (daily doses between 100 and 1000 micrograms)
Number of subjects: 7
Study 2706913 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration (20 Hz, 20 m/s2 RMS)
Number of subjects: 14
Study 2706913 — intervention group
Group type: COMPARATOR
Intervention: No vibration (control)
Number of subjects: 14
Study 341935 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine 1% with adrenaline (1:200 000)
Number of subjects: 40
Study 341935 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine 1.5% with adrenaline (1:200 000)
Number of subjects: 40
Study 341935 — intervention group
Group type: COMPARATOR
Intervention: Etidocaine 1% without adrenaline
Number of subjects: 40
Study 341935 — intervention group
Group type: COMPARATOR
Intervention: Etidocaine 1.5% without adrenaline
Number of subjects: 40
Study 31315910 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 14174
Study 31315910 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip Circumference
Number of subjects: 14174
Study 31315910 — intervention group
Group type: EXPERIMENTAL
Intervention: ADpSGEGDFXAEGGGVR* (fibrinogen-cleavage peptide)
Number of subjects: 14174
Study 31315910 — intervention group
Group type: EXPERIMENTAL
Intervention: O-sulfo-l-tyrosine
Number of subjects: 14174
Study 31315910 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Adenocarcinoma
Number of subjects: 14174
Study 29454009 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia for 24 hours (33 ± 1 °C)
Number of subjects: 34
Study 29454009 — intervention group
Group type: COMPARATOR
Intervention: Hypothermia for 72 hours (33 ± 1 °C)
Number of subjects: 34
Study 26305143 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg tolterodine ER
Number of subjects: 95
Study 26305143 — intervention group
Group type: COMPARATOR
Intervention: 4 mg tolterodine ER
Number of subjects: 95
Study 24865872 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI)
Number of subjects: 330
Study 24865872 — intervention group
Group type: COMPARATOR
Intervention: Assessment only control
Number of subjects: 330
Study 24865872 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 330
Study 22112544 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate FSG at baseline (defined as depth of insertion <50 cm or visual inspection limited to <90% of mucosal surface without detection of a polyp or mass)
Number of subjects: 64554
Study 22112544 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate FSG due to depth of insertion <50 cm
Number of subjects: 64554
Study 22112544 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate FSG despite adequate depth of insertion
Number of subjects: 64554
Study 22112544 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and sex factors associated with inadequate FSG
Number of subjects: 64554
Study 22112544 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI > 30 kg/m(2))
Number of subjects: 64554
Study 22112544 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate FSG at baseline
Number of subjects: 64554
Study 18440668 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate tissue adhesive
Number of subjects: 186
Study 18440668 — intervention group
Group type: COMPARATOR
Intervention: Conventional suture
Number of subjects: 186
Study 17585002 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery (expedited, approximately four weeks)
Number of subjects: 306
Study 17585002 — intervention group
Group type: COMPARATOR
Intervention: Control (routine, 12 months wait)
Number of subjects: 306
Study 15035964 — intervention group
Group type: EXPERIMENTAL
Intervention: Grimaldi's method
Number of subjects: 40
Study 15035964 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 11511433 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 94
Study 11511433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 9747999 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary prostheses provided to doubtful ambulators, double amputees, blind persons, and those with psychiatric disorders.
Number of subjects: 60
Study 9747999 — intervention group
Group type: COMPARATOR
Intervention: Prosthetic limb provision policy.
Number of subjects: 60
Study 7851032 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (mean dose: 6.4 +/- 4 mg) for 6 months
Number of subjects: 19
Study 7851032 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 patients)
Number of subjects: 19
Study 3385411 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive feedback
Number of subjects: 90
Study 3385411 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative feedback
Number of subjects: 90
Study 3385411 — intervention group
Group type: COMPARATOR
Intervention: No feedback (Control)
Number of subjects: 90
Study 3385411 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood induction (Velten's procedure)
Number of subjects: 90
Study 3385411 — intervention group
Group type: EXPERIMENTAL
Intervention: Bogus feedback
Number of subjects: 90
Study 29111784 — intervention group
Group type: COMPARATOR
Intervention: Bright Light Therapy (BLT) only
Number of subjects: 62
Study 29111784 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Bright Light Therapy (BLT) and Wake Therapy (WT)
Number of subjects: 62
Study 28195995 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-004HR (4-, 10-, and 25-μg)
Number of subjects: 764
Study 28195995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 764
Study 28195995 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-004HR
Number of subjects: 764
Study 25140047 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 0
Study 25140047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23450660 — intervention group
Group type: EXPERIMENTAL
Intervention: Pridopidine 90 mg/day
Number of subjects: 227
Study 23450660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 22017799 — intervention group
Group type: COMPARATOR
Intervention: Passive warming with blankets
Number of subjects: 48
Study 22017799 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive warming with blankets + active warming using a chemical heat pad
Number of subjects: 48
Study 18440821 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (0.75-10mg) daily for 21 days
Number of subjects: 11
Study 18440821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 17137905 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 35
Study 17137905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 12648202 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of hyperbaric bupivacaine + 10 microg fentanyl (B3F)
Number of subjects: 100
Study 12648202 — intervention group
Group type: COMPARATOR
Intervention: 4 mg of hyperbaric bupivacaine (B4)
Number of subjects: 100
Study 12648202 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 16198237 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone (administered to 27 patients: GIa, n = 13; GIIa, n = 14)
Number of subjects: 51
Study 16198237 — intervention group
Group type: COMPARATOR
Intervention: Control group (GIb, n = 11; GIIb, n = 13)
Number of subjects: 51
Study 10512125 — intervention group
Group type: EXPERIMENTAL
Intervention: Miso soup intake
Number of subjects: 999
Study 10512125 — intervention group
Group type: EXPERIMENTAL
Intervention: Pickles intake (excluding salted fish)
Number of subjects: 999
Study 10512125 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybeans intake
Number of subjects: 999
Study 10512125 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofu consumption
Number of subjects: 999
Study 7491379 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 71
Study 7491379 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 71
Study 7491379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 2321570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation (65 mg/d for 2 weeks, 5 mg/d for 4 weeks, 605 mg/d for 3 weeks, 5 mg/d for 4 weeks, average 375 mg/d for 1 week)
Number of subjects: 11
Study 2321570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation
Number of subjects: 11
Study 2321570 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid deficiency
Number of subjects: 11
Study 6270996 — intervention group
Group type: EXPERIMENTAL
Intervention: Various test diets (specific dietary components)
Number of subjects: 50
Study 6270996 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 50
Study 31062207 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Number of subjects: 25
Study 31280826 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track protocol in the emergency department (ED)
Number of subjects: 126
Study 31280826 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis in ED
Number of subjects: 126
Study 31280826 — intervention group
Group type: COMPARATOR
Intervention: Prehospital delay
Number of subjects: 126
Study 28296581 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib 300 mg orally twice per day
Number of subjects: 46
Study 26255281 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine (BA) supplementation (800 mg BA + 8 g dextrose, 4 doses/day for 28 days)
Number of subjects: 22
Study 26255281 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA; 8 g dextrose, 4 doses/day for 28 days)
Number of subjects: 22
Study 23826907 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfannenstiel laparoendoscopic single-site donor nephrectomy (LESS-DN)
Number of subjects: 29
Study 23826907 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic donor nephrectomy (LDN)
Number of subjects: 29
Study 20947819 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (8 mg/d)
Number of subjects: 37
Study 20947819 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2 g/d)
Number of subjects: 37
Study 19042115 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC 50/250microg
Number of subjects: 282
Study 19042115 — intervention group
Group type: COMPARATOR
Intervention: FP 250microg
Number of subjects: 282
Study 19042115 — intervention group
Group type: COMPARATOR
Intervention: SAL 50microg
Number of subjects: 282
Study 19042115 — intervention group
Group type: EXPERIMENTAL
Intervention: General treatment
Number of subjects: 282
Study 16973786 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT) over 6 months
Number of subjects: 58
Study 16973786 — intervention group
Group type: COMPARATOR
Intervention: Monthly monitoring
Number of subjects: 58
Study 13680307 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 160
Study 13680307 — intervention group
Group type: COMPARATOR
Intervention: Control (non-obese patients)
Number of subjects: 160
Study 11529246 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV-GAD gene transfer
Number of subjects: 20
Study 11529246 — intervention group
Group type: COMPARATOR
Intervention: Control group (physiological saline)
Number of subjects: 20
Study 9631952 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide (0.05 mg BID) for 8 days
Number of subjects: 12
Study 9631952 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 days
Number of subjects: 12
Study 7836186 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training program (16 weeks)
Number of subjects: 21
Study 7836186 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 21
Study 30340618 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatrician-led admission avoidance hospital at home
Number of subjects: 36
Study 30340618 — intervention group
Group type: COMPARATOR
Intervention: Inpatient admission
Number of subjects: 36
Study 28533093 — intervention group
Group type: EXPERIMENTAL
Intervention: LAIV H5N2 vaccine (two intranasal doses of 0.25 mL per nostril, 21 days apart)
Number of subjects: 152
Study 28533093 — intervention group
Group type: EXPERIMENTAL
Intervention: LAIV H5N2 vaccine (two doses)
Number of subjects: 152
Study 28533093 — intervention group
Group type: COMPARATOR
Intervention: H5N1 booster vaccine (one intramuscular dose of 0.5 mL)
Number of subjects: 152
Study 28533093 — intervention group
Group type: EXPERIMENTAL
Intervention: LAIV H5N2 vaccine
Number of subjects: 152
Study 26556097 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant 30 mg
Number of subjects: 88
Study 26556097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 23314060 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma protein panel (5 proteins identified)
Number of subjects: 167
Study 23314060 — intervention group
Group type: COMPARATOR
Intervention: Training sample of plasma analytes (107 analytes)
Number of subjects: 167
Study 23314060 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological pathway analysis
Number of subjects: 167
Study 23314060 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein E
Number of subjects: 167
Study 21187295 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day)
Number of subjects: 114
Study 21187295 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 tablet/day)
Number of subjects: 114
Study 18361342 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips Sonicare FlexCare
Number of subjects: 93
Study 18361342 — intervention group
Group type: COMPARATOR
Intervention: Oral-B Triumph
Number of subjects: 93
Study 18361342 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference between FlexCare and Triumph
Number of subjects: 93
Study 18361342 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined overall treatment effect from two studies
Number of subjects: 93
Study 17161267 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein ablation (CPVA)
Number of subjects: 198
Study 17161267 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy (ADT)
Number of subjects: 198
Study 12708602 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-LOT (90 mg coumarin + 540 mg troxerutin/d)
Number of subjects: 231
Study 12708602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 12708602 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2A6 polymorphism
Number of subjects: 231
Study 10997840 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal videotrainer skills training
Number of subjects: 22
Study 10997840 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 8715321 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique of drop administration taught to patients
Number of subjects: 0
Study 8715321 — intervention group
Group type: COMPARATOR
Intervention: Home caregiver applying drops
Number of subjects: 0